Derrey S, Penchet G, Thines L, Lonjon M, David P, Bataille B, Emery E, Lubrano V, Laguarrigue J, Bresson D, Pelissou I, Irthum B, Lejeune J-P, Proust F
Department of Neurosurgery, Rouen University Hospital, 1, rue de Germont, 76031 Rouen cedex, France.
Department of Neurosurgery, Rouen University Hospital, 1, rue de Germont, 76031 Rouen cedex, France.
Neurochirurgie. 2015 Dec;61(6):371-7. doi: 10.1016/j.neuchi.2013.11.006. Epub 2014 Mar 16.
Giant intracranial aneurysms represent a major therapeutic challenge for each surgical team. The aim of our study was to extensively review the French contemporary experience in treating giant intracranial aneurysms in order to assess the current management.
This retrospective multicenter study concerned consecutive patients treated for giant intracranial aneurysms (2004-2008) in different French university hospitals (Bordeaux, Caen, Clermont-Ferrand, Lille, Lyon, Nice, Paris-Lariboisière, Rouen et Toulouse). Different variables were analyzed: the diagnostic circumstances, the initial clinical status based on the WFNS scale, aneurysmal features and exclusion procedure. At 6 months, the outcome was evaluated according to the modified Rankin Scale (mRS): favorable (mRS 0-2) and unfavorable (mRS 3-6). A multivariate logistic regression model included all the independent variables with P<0.25 in the univariate analysis (P<0.05).
A total of 79 patients with a mean age of 51.5 ± 1.6 years (median: 52 years; range: 16-79) were divided into two groups, with the ruptured group (n=26, 32.9%) significantly younger (P<0.05, Student's-t-test) than the unruptured group (n=53, 67.1%). After SAH, the initial clinical status was good in 12 patients (46.2%), and in the unruptured group, the predominant diagnosis circumstance was a pseudo-tumor syndrome occurring in 22 (41.5%). The first procedure of aneurysm treatment in the global population was endovascular in 42 patients (53.1%), microsurgical in 29 (36.7%) and conservative in 8 (10.2). An immediate neurological deterioration was reported in 38 patients (48.1%) after endovascular treatment in 19 (45.2% of endovascular procedures), after miscrosurgical in 15 (51.7% of microsurgical procedures) and after conservative in 4 (the half). At 6 months, the outcome was favorable in 45 patients (57%) and after multivariate analysis, the predictive factors of favorable outcome after management of giant cerebral aneurysm were the initial good clinical status in cases of SAH (P<0.002), the endovascular treatment (P<0.005), and the absence of neurological deterioration (P<0.006). The endovascular procedure was obtained as a predictive factor because of the low risk efficacy of indirect procedures, in particular a parent vessel occlusion.
The overall favorable outcome rate concerned 57% of patients at 6 months despite 53.8% of poor initial clinical status in cases of rupture. The predictive factors for favorable outcome were good clinical status, endovascular treatment and the absence of postoperative neurological deterioration. Endovascular treatment should be integrated into the therapeutic armenmatarium against giant cerebral aneurysms but the durability of exclusion should be taken into account during the multidisciplinary discussion by the neurovascular team.
巨大颅内动脉瘤对每个手术团队来说都是一项重大的治疗挑战。我们研究的目的是广泛回顾法国当代治疗巨大颅内动脉瘤的经验,以评估当前的治疗方法。
这项回顾性多中心研究涉及2004年至2008年期间在法国不同大学医院(波尔多、卡昂、克莱蒙费朗、里尔、里昂、尼斯、巴黎拉里博瓦西埃、鲁昂和图卢兹)接受巨大颅内动脉瘤治疗的连续患者。分析了不同变量:诊断情况、基于世界神经外科联合会(WFNS)量表的初始临床状态、动脉瘤特征和排除程序。在6个月时,根据改良Rankin量表(mRS)评估结果:良好(mRS 0 - 2)和不良(mRS 3 - 6)。多变量逻辑回归模型纳入了单变量分析中P<0.25(P<0.05)的所有独立变量。
共有79例患者,平均年龄51.5±1.6岁(中位数:52岁;范围:16 - 79岁),分为两组,破裂组(n = 26,32.9%)比未破裂组(n = 53,67.1%)明显年轻(P<0.05,Student's - t检验)。蛛网膜下腔出血(SAH)后,12例患者(46.2%)初始临床状态良好,在未破裂组中,主要诊断情况是22例(41.5%)出现假瘤综合征。总体人群中动脉瘤治疗的首次程序为血管内治疗42例(53.1%),显微手术29例(36.7%),保守治疗8例(10.2%)。血管内治疗后19例(占血管内治疗程序的45.2%)、显微手术后15例(占显微手术程序的51.7%)、保守治疗后4例(一半)报告有38例患者(48.1%)出现立即神经功能恶化。在6个月时,45例患者(57%)结果良好,多变量分析后,巨大脑动脉瘤治疗后良好结果的预测因素是SAH病例中初始良好的临床状态(P<0.002)、血管内治疗(P<0.005)以及无神经功能恶化(P<0.006)。血管内程序成为预测因素是因为间接程序,特别是母血管闭塞的低风险疗效。
尽管破裂病例中53.8%的初始临床状态较差,但6个月时总体良好结果率为57%的患者。良好结果的预测因素是良好的临床状态、血管内治疗和术后无神经功能恶化。血管内治疗应纳入针对巨大脑动脉瘤的治疗手段,但在神经血管团队的多学科讨论中应考虑排除的耐久性。